Twist Bioscience Corp(TWST)Stock Analysis

TWST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Twist Bioscience Corp (TWST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TWST at 33.3/100 on a 32-signal composite quality model, placing it at rank #2,237 of 2,879 stocks — the bottom half of the AI-ranked universe. TWST scores in the top quartile across revenue growth (80.3). Areas of concern include free cash flow (13.5) and balance sheet strength (14.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Twist Bioscience Corp reports quarterly revenue of $110.7M, net income of $-44.0M, an operating margin of -41.4%. Top institutional holders of TWST by reported 13-F value include Artisan Partners Limited Partnership, ARK Investment Management, BlackRock,, based on the most recent SEC filings. TWST trades on the Nasdaq exchange and files with the SEC under CIK 1581280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TWST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Twist Bioscience Corp directly from SEC EDGAR. Twist Bioscience Corp's 13F Pro composite quality score has ranged between 8 and 68 since 2023, currently 33.3 — an improving long-term trajectory across 43 quarterly and live scoring snapshots.